Tag: Alliqua

YARDLEY, Pa. - Wound care provider Alliqua BioMedical reported total revenue of $5.5 million for the second quarter of 2016, up 75% year-over-year, compared to revenue of $3.1 million for the same period last year. Income from operations was $2.1 million for the quarter this year, compared to a loss of $8.4 million for the quarter last year. Alliqua reported total revenue of $8.4 million for the first six months of 2016, up 108%, compared to revenue of $4 million for the same period last year. Net...

YARDLEY, Pa., and CHARLOTTE, N.C. - Alliqua BioMedical, a provider of wound care products, has signed a definitive agreement with BSN Medical for the exclusive distribution rights for its Sorbion, Sachet and Sorbion Sana primary dressings in the U.S., Canada and Latin America. Per the agreement, BSN will pay Alliqua $4.4 million to purchase the rights of Alliqua's existing distribution agreement with Sorbion GmbH & Co KG, now owned by BSN Medical. “The sale of Alliqua's exclusive distribution...

LANGHORNE, Pa. - Alliqua BioMedical, a provider of advanced wound care products, has raised $34.5 million through a public offering. The company, listed on the NASDAQ as ALOA, sold about 6.6 million shares of its common stock at a price of $4.55 per share. Alliqua plans to use the net proceeds from the offering to “fund the commercial expansion of its marketed products, to opportunistically pursue additional product platforms, and for working capital and general corporate purposes,” according...

WASHINGTON - AAHomecare plans to build a system to track the Medicare audits that are devastating HME providers, the association announced during its Washington Legislative Conference last week. “Good data informs good decisions,” said Tom Ryan, president and CEO of the association, in a release. “We're ready to work on behalf of the industry to collect and quantify the impacts of audits and present compelling facts that policymakers cannot ignore.” AAHomecare worked with...

LANGHORNE, Pa. - Alliqua, a provider of advanced wound care products, has acquired Choice Therapeutics for $4 million in stock and cash. The agreement, effective May 5, provides for an additional contingency payment of up to $5 million in stock or cash if stated revenue thresholds are reached over the next three years ending April 30, 2017. Alliqua has acquired Choice's wound care portfolio, its technology platform, and its sales and marketing team. The portfolio includes a TheraBond Antimicrobial...

ATLANTA - Brightree has acquired McKinney, Texas-based MedAct, adding 330 HME providers to its customer base. “With the addition of MedAct, we are expanding our market reach to include some of the industry's most nimble HME providers,” said Dave Cormack, president and CEO of Brightree, in a release. MedAct's customers will join Brightree's more than 3,000 customers. Under the terms of the agreement, MedAct CEO Gregg Timmons joins Brightree as executive vice president, MedAct Division....

LANGHORNE, Pa. - Alliqua has closed a set of deals that brings the company two new products and $13 million in investments, the Philadelphia Business Journal reports. “Alliqua now has significant capital to bring our business plans to fruition,” said CEO David Johnson in the story. In a deal with Celgene, Alliqua obtained the rights to develop and market advanced wound care products Biovance and Extracellular Matrix, and Celgene purchased $6 million in Alliqua stock. Separately, Broadfin...

WASHINGTON - A meeting with CMS and congressional staff on DME competitive bidding, originally cancelled due to the government shutdown, has been set for 11 a.m., Monday, Nov. 18, says The VGM Group. Because the briefings, for staff of the Energy and Commerce and Ways and Means committees, will not be public, VGM and AAHomecare are calling on providers to contact their members of Congress to urge them to attend.Employees return to Invacare facilityELYRIA, Ohio - A “small number” of employees...

LANGHORNE, Pa. - Alliqua has obtained $1 million in financing from Crossover Healthcare Fund to fund key initiatives in the wound care space, the company announced Nov. 12. The biopharmaceutical company will put the money toward sales and marketing of hydrogel products sold under the SilverSeal brand, and its sorbion sachet S and sorbion Sana wound-care products. The financing is in the form of 250,000 shares of Series A Preferred Stock, which can be converted into 11,111,111 shares of common stock....